<DOC>
	<DOC>NCT01386684</DOC>
	<brief_summary>The purpose of this study is to evaluate the Canadian Real Life Evaluation of the Effectiveness of Lupron in the Management of Prostate Cancer.</brief_summary>
	<brief_title>Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study</brief_title>
	<detailed_description>This is a Canadian Post Marketing Observational Study utilizing a prospective cohort design. Patients with Prostate Cancer who are prescribed Lupron will be entered into the study cohort and will be followed for a maximum of 36 months with recommended assessments at 3, 6, 12, 18, 24, 30 and 36 months after baseline. Treatment of the patients and follow up will be according to the physician's judgment, regional regulations and the product monograph.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>i. Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel ii. Diagnosed with Prostate Cancer iii. Prescribed Lupron as part of his treatment by his treating physician i. Currently participating in another prospective study including controlled clinical trials and observational studies. â€¢ Exclusion of patient participating in other observational studies is necessary in order to prevent overrepresentation of specific patients in different studies, practical considerations regarding authority to utilize the patient's data and statistical issues related to lack of independence of the observations in different studies triggering multiplicity issues ii. Patient cannot or will not sign informed consent iii. Survival expectancy less than 23 years as per the treating physician's judgment iv. Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of Prostate Cancer v. History of alcohol or drug abuse vi. No longer than 6 months of therapy if currently on luteinizing hormonereleasing hormone (LHRH) treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>